J. Hernández‐Boluda

发表

Danazol treatment of idiopathic myelofibrosis with severe anemia.

E. Montserrat, F. Cervantes, J. Hernández-Boluda, 2000, Haematologica.

Long-term results of prednisone treatment for the anemia of myelofibrosis

F. Cervantes, J. Hernández-Boluda, V. García-Gutiérrez, 2016, Leukemia & lymphoma.

Idiopathic Myelofibrosis Associated with Primary Biliary Cirrhosis

L. Rosiñol, F. Cervantes, J. Hernández-Boluda, 2002, Leukemia & lymphoma.

Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis

E. Montserrat, N. Villamor, F. Cervantes, 2000, European journal of haematology.

Polymyositis after donor lymphocyte infusion

C. Solano, J. Hernández-Boluda, C. Arbona, 2012, International Journal of Hematology.

Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens

M. Tormo, E. Albert, C. Solano, 2020, Journal of Infection.

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

V. Guillem, C. Solano, P. Eroles, 2015, Leukemia research.

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

M. Tormo, C. Solano, D. Navarro, 2022, Journal of Hematology & Oncology.

Community‐acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus‐bacterial mixed infections

V. Vinuesa, C. Solano, E. Giménez, 2018, Transplant infectious disease : an official journal of the Transplantation Society.

Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia.

I. Marugán, V. Guillem, J. Cervera, 2012, Leukemia research.

Prognostic factors in chronic myeloid leukaemia.

F. Cervantes, J. Hernández-Boluda, J. Hernández‐Boluda, 2009, Best practice & research. Clinical haematology.

Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia

E. Montserrat, D. Costa, F. Cervantes, 2001, Annals of Hematology.

Impact of molecular profiling on the management of patients with myelofibrosis.

J. Hernández-Boluda, Irene Pastor-Galán, Iván Martín, 2022, Cancer treatment reviews.

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients

I. Benet, C. Solano, D. Navarro, 2010, Bone Marrow Transplantation.

Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

Á. Payer, M. Ramírez, F. Cervantes, 2020 .

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

M. Robin, I. Yakoub-Agha, M. Aljurf, 2021, Leukemia.

A risk‐adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study

M. Terol, C. Solano, D. Navarro, 2017, Transplant infectious disease : an official journal of the Transplantation Society.

The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey

C. Solano, E. Giménez, D. Navarro, 2019, Bone Marrow Transplantation.

Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients

C. Solano, E. Giménez, D. Navarro, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study

M. Terol, C. Solano, E. Giménez, 2017, Biology of Blood and Marrow Transplantation.

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.

M. Tormo, J. Pérez-Simón, Arturo Pereira, 2022, Leukemia research.

A polymorphism in the TYMP gene is associated with the outcome of HLA‐identical sibling allogeneic stem cell transplantation

I. Buño, C. Solano, S. Brunet, 2013, American journal of hematology.

Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study

V. Vinuesa, C. Solano, E. Giménez, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia

M. Tormo, V. Vinuesa, C. Solano, 2019, Journal of Infection.

Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients.

E. Montserrat, M. Paz, M. Esteller, 2003, Experimental hematology.

The changing profile of Ph-positive chronic myeloid leukemia at presentation: possible impact of earlier diagnosis on survival.

A. Ferrer, E. Montserrat, F. Cervantes, 1999, Haematologica.

A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.

J. Queraltó, M. Terol, J. Sierra, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

J. Hernández-Boluda, V. García-Gutiérrez, V. García‐Gutiérrez, 2022, Expert review of hematology.

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

Á. Payer, M. Ramírez, A. Rosell, 2018, Annals of Hematology.

Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients

D. Colomer, B. Bellosillo, A. Julià, 2007, Leukemia.

Risk factors for non‐melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera

V. Guillem, Arturo Pereira, J. Martínez-López, 2016, European journal of haematology.

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.

J. Sierra, C. Solano, E. Giménez, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

B. Bellosillo, Arturo Pereira, A. Angona, 2022, Cancer.

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

J. Martínez-López, A. Bárez, M. Mata, 2016, British journal of haematology.

Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

Arturo Pereira, F. Cervantes, J. Hernández-Boluda, 2013, Annals of Hematology.

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.

B. Bellosillo, V. Vicente, Arturo Pereira, 2012, Blood.

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

B. Bellosillo, A. Angona, B. Navarro, 2011, British journal of haematology.

Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea

J. Cervera, B. Bellosillo, E. Such, 2020, Leukemia.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Blood Cancer Journal.

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, M. Robin, 2021, Bone Marrow Transplantation.

Transplantation algorithm for myelofibrosis in 2022 and beyond.

J. Hernández-Boluda, T. Czerw, J. Hernández‐Boluda, 2022, Best practice & research. Clinical haematology.

Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)

N. Kröger, M. Robin, P. Chevallier, 2020, American journal of hematology.

European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.

I. Yakoub-Agha, D. Mclornan, J. Hernández-Boluda, 2020, Current research in translational medicine.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

N. Kröger, S. Iacobelli, L. Kanz, 2020, Leukemia.

Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT.

N. Kröger, L. Kanz, M. Robin, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acute Leukemias Interferon α plus intermittent oral AraC ocfosfate ( YNK-01 ) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon

S. Brunet, R. Martino, F. Cervantes, 2001 .

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.

Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia

D. Colomer, B. Bellosillo, Arturo Pereira, 2017, British journal of haematology.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

F. Sánchez-Guijo, Arturo Pereira, F. Cervantes, 2018, Blood Cancer Journal.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

T. Barbui, A. Patriarca, P. Guglielmelli, 2021, Leukemia.

Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported.

R. Mesa, L. Masarová, Jason A Taylor, 2020, Leukemia research.

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results

Arturo Pereira, F. Cervantes, J. Hernández-Boluda, 2015, Annals of Hematology.

Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis.

F. Sánchez-Guijo, Arturo Pereira, J. Mora, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

M. Ramírez, Arturo Pereira, F. Cervantes, 2018, British journal of haematology.

Predictive factors for anemia response to erythropoiesis‐stimulating agents in myelofibrosis

F. Cervantes, J. Martínez-López, J. Hernández-Boluda, 2017, European journal of haematology.

Darbepoetin‐alpha for the anaemia of myelofibrosis with myeloid metaplasia

E. Montserrat, F. Cervantes, A. Sureda, 2006, British journal of haematology.

Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature

E. Montserrat, M. Torrebadell, F. Cervantes, 2004, British journal of haematology.

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

H. Einsele, N. Kröger, I. Yakoub-Agha, 2021, American journal of hematology.

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

J. Hernández-Boluda, V. García‐Gutiérrez, J. Hernández‐Boluda, 2019, Front. Oncol..

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

D. Colomer, Marcos González, Arturo Pereira, 2010, Haematologica.

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

Arturo Pereira, J. Martínez-López, E. Luño, 2014, Haematologica.

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

D. Colomer, D. Costa, V. Guillem, 2011, Leukemia research.

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

J. Hernández-Boluda, V. García-Gutiérrez, V. García‐Gutiérrez, 2020, Journal of clinical medicine.

Prognostic risk models for transplant decision-making in myelofibrosis

Á. Payer, M. Ramírez, Arturo Pereira, 2018, Annals of Hematology.

Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.

I. Marugán, M. Tormo, D. Roda, 2009, Leukemia research.

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

J. Martínez-López, R. Ayala, J. Hernández-Boluda, 2023, EJHaem.

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

A. Jiménez-Velasco, J. Martínez-López, J. Hernández-Boluda, 2017, Journal of health economics and outcomes research.

Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain

F. Cervantes, J. Hernández-Boluda, C. Besses, 2014, Journal of Medical Economics.

Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

E. Albert, C. Solano, D. Navarro, 2020, Bone Marrow Transplantation.

Prospective randomized study comparing myeloablative unrelated umbilical-cord blood transplant versus HLA-haploidentical related stem cell transplant for adults with hematologic malignancies.

C. Solano, M. Sanz, J. Sanz, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

M. Griesshammer, P. Guglielmelli, A. Vannucchi, 2016, Haematologica.

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.

B. Bellosillo, V. Vicente, Arturo Pereira, 2010, Blood.

CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

A. Mead, M. Rozman, N. Cross, 2022, Blood advances.

Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis

I. Yakoub-Agha, D. Mclornan, A. Radujkovic, 2022, British journal of haematology.

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

S. Mustjoki, J. Lipton, K. Porkka, 2021, Leukemia & lymphoma.

Treatment of elderly patients with AML: results of an individualized approach.

J. Esteve, E. Montserrat, J. Sierra, 1998, Haematologica.